{"id":9059,"date":"2023-12-02T12:12:25","date_gmt":"2023-12-02T11:12:25","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=9059"},"modified":"2023-12-21T12:16:01","modified_gmt":"2023-12-21T11:16:01","slug":"a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/","title":{"rendered":"A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ishihara+H&amp;cauthor_id=38041760\">Hikaru Ishihara<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/#full-view-affiliation-1\">1<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Watanabe+T&amp;cauthor_id=38041760\">Tatsuyuki Watanabe<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kumei+S&amp;cauthor_id=38041760\">Shinsuke Kumei<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kume+K&amp;cauthor_id=38041760\">Keiichiro Kume<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yoshikawa+I&amp;cauthor_id=38041760\">Ichiro Yoshikawa<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Harada+M&amp;cauthor_id=38041760\">Masaru Harada<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/#full-view-affiliation-2\">2<\/a><\/sup> Clin J Gastroenterol.\u00a02023 Dec 2.\u00a0doi: 10.1007\/s12328-023-01887-7.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>A 68-year-old man developed immune-related adverse event (irAE) colitis after the initiation of nivolumab and ipilimumab combination therapy for malignant melanoma. We diagnosed the patient with grade 3 irAE colitis and started prednisolone (1 mg\/kg\/day). Although the symptom improved once, it worsened along with the tapering of prednisolone. Therefore, we started infliximab (IFX). However, symptoms did not improve after two doses of IFX. We discontinued IFX and initiated vedolizumab (VED). Because VED alone did not improve the symptom, we started granulocyte-monocyte apheresis (GMA). Twelve weeks after the onset, the colitis was in remission. Therefore, in addition to vedolizumab, GMA may be considered in cases refractory to treatment.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38041760\/\">A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy &#8211; PubMed (nih.gov)<\/a><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01887-7\">A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte\u2013monocyte apheresis combination therapy | Clinical Journal of Gastroenterology (springer.com)<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Hikaru Ishihara\u00a01,\u00a0Tatsuyuki Watanabe\u00a02,\u00a0Shinsuke Kumei\u00a02,\u00a0Keiichiro Kume\u00a02,\u00a0Ichiro Yoshikawa\u00a02,\u00a0Masaru Harada\u00a02 Clin J Gastroenterol.\u00a02023 Dec 2.\u00a0doi: 10.1007\/s12328-023-01887-7. A 68-year-old man developed immune-related adverse event (irAE) colitis after the initiation of nivolumab and ipilimumab combination therapy for malignant melanoma. We diagnosed the patient with grade 3 irAE colitis and started prednisolone (1 mg\/kg\/day). Although the symptom improved once, it worsened [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[778,147,303,424,691,109,461,485,306,66],"class_list":["post-9059","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-adverse-event","scientific_tags-clinical-remission","scientific_tags-combination","scientific_tags-gma","scientific_tags-immune-checkpoint-inhibitors","scientific_tags-infliximab","scientific_tags-refractory","scientific_tags-steoids","scientific_tags-ulcerative-colitis","scientific_tags-vedolizumab"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Hikaru Ishihara\u00a01,\u00a0Tatsuyuki Watanabe\u00a02,\u00a0Shinsuke Kumei\u00a02,\u00a0Keiichiro Kume\u00a02,\u00a0Ichiro Yoshikawa\u00a02,\u00a0Masaru Harada\u00a02 Clin J Gastroenterol.\u00a02023 Dec 2.\u00a0doi: 10.1007\/s12328-023-01887-7. A 68-year-old man developed immune-related adverse event (irAE) colitis after the initiation of nivolumab and ipilimumab combination therapy for malignant melanoma. We diagnosed the patient with grade 3 irAE colitis and started prednisolone (1 mg\/kg\/day). Although the symptom improved once, it worsened [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-21T11:16:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/\",\"name\":\"A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-12-02T11:12:25+00:00\",\"dateModified\":\"2023-12-21T11:16:01+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/","og_locale":"es_ES","og_type":"article","og_title":"A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy - Adacyte","og_description":"Hikaru Ishihara\u00a01,\u00a0Tatsuyuki Watanabe\u00a02,\u00a0Shinsuke Kumei\u00a02,\u00a0Keiichiro Kume\u00a02,\u00a0Ichiro Yoshikawa\u00a02,\u00a0Masaru Harada\u00a02 Clin J Gastroenterol.\u00a02023 Dec 2.\u00a0doi: 10.1007\/s12328-023-01887-7. A 68-year-old man developed immune-related adverse event (irAE) colitis after the initiation of nivolumab and ipilimumab combination therapy for malignant melanoma. We diagnosed the patient with grade 3 irAE colitis and started prednisolone (1 mg\/kg\/day). Although the symptom improved once, it worsened [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/","og_site_name":"Adacyte","article_modified_time":"2023-12-21T11:16:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/","name":"A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-12-02T11:12:25+00:00","dateModified":"2023-12-21T11:16:01+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-of-refractory-immune-checkpoint-inhibitor-induced-colitis-improved-by-the-treatment-with-vedolizumab-and-granulocyte-monocyte-apheresis-combination-therapy\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/9059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=9059"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=9059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}